We're developing innovative treatments for Alzheimer's disease.
Alzheimer's disease is a progressive neurodegenerative disorder characterized by the formation of toxic amyloid-β oligomers and plaques. Amyloid-β misfolding and aggregation exacerbate cognitive impairment in Alzheimer’s disease. Therefore, the clearance of these pre-existing amyloid-β aggregates can lead to a promising disease-modifying treatment. Our lead candidate, AS-S701, is a small molecule drug that directly disaggregates all types of amyloid-β aggregates, including oligomers and plaques, into non-toxic monomers. AS-S701 is a chemical version of those amyloid clearing immunotherapy.
Toll-like receptor-2 (TLR2) is activated by the TLR2 ligand, such as lipoproteins or amyloid-β, and the activated TLR2 triggers the MyD88/NF-κB signaling pathway. AS-M801, a TLR2 antagonistic monoclonal antibody, can suppress inflammatory response through the inactivation of TLR2, preventing onset of the MyD88/NF-κB signaling pathway and maintaining homeostasis in the immune system.